BioSpace News Archive

After its parent company AGC Inc. acquired 100% of the shares of MolMed S.p.A. on September 30, 2020, AGC Biologics announced that MolMed’s entity name has been changed to AGC Biologics S.p.A.

Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder.

The global neuroendocrine tumor treatment market is expected to witness stupendous growth during the forecast period 2018 – 2028.

Diagnosis through radiation and safety equipment are largely used in hospitals and clinics treating tumor and cancer.

Companies in the foot and mouth disease vaccines market are capitalizing on value-grab opportunities to develop COVID-19 vaccines that hold promising potentials to protect animals.

Fibrotic bronchoscopy is used to identify the cause of lung problems. It may detect tumors, signs of infection, excess mucus in the airways, and bleeding or blockages in the lungs.

The global drug discovery services market is thriving on account of the rising impetus given to research and development across several industrial.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock.

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2020.

PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2020.